baber/WOPTO huggingface dataset:
Patent CA-2690409-A1 (CA)
Title: System and process for handling, prepping, tagging and shipping plants
Inventor: MORI WILLIAM
IPC: G06Q50/00
Filed: 2010-01-18
Abstract: A plant handling, tagging and shipping system includes a flood trailer towed by a cart for delivering potted plants from a grow site to a prepping station while also soaking the pots, an on-demand tag-printing system for printing plant tags based on customized client data, and a conveyor system that enables workers to trim, weed, clean, and tag the plants as they travel along the conveyor. This novel system and process for handling, tagging and shipping plants provides enormous efficiencies as compared with traditional processes.
Patent CA-2695365-A1 (CA)
Inventor: FINE JAY S
IPC: A61P11/06
Filed: 2008-07-29
Abstract: The present application discloses a method of treating a CXCR3 chemokine receptor mediated disease selected from the group consisting of chronic obstructive pulmonary disease (COPD), asthma, sarcoidosis, systemic lupus erythematosus (SLE), alkylosing spondylitis, fibrotic diseases, pulmonary fibrosis, alopecia areata, scleroderma, lichen planus erythematosus, discoid lupus erythematosus, dermatomyositis, Behcet's disease, Wegener's disease, atopic dermatitis, and graft-vs-host disease (GVHD) in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound having the general structure shown in Formula 1: Formula 1 or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein.
Patent CA-2695583-A1 (CA)
Inventor: TIAN FENG
IPC: C07C233/11
Filed: 2008-08-13
Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistence and hyperglycemia.  The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
Patent CA-2696057-A1 (CA)
Title: Bicycle carry rack assembly
Inventor: WANG CHIU-KUEI
IPC: B60R9/10
Filed: 2010-03-15
Abstract: A bicycle carry rack assembly includes a connection bar with two adjusting plates selectively connected thereto so as to be connected with different sizes of the connection tube on the vehicles. A U-shaped frame is connected to the connection bar by two boards which have multiple holes and the connection bar can be connected to different holes by pins to set the positions of the support unit on the frame.  The frame and the support unit can be pivoted upward or downward relative to the connection bar for achieving different purposes. The support unit includes two rails on which positioning members are connected to support bicycles, a positioning bar is pivotably connected between the two rails and can be set at different angular positions.
Patent CA-2697326-A1 (CA)
Inventor: SHI YONG-CHENG
IPC: A23L7/10
Filed: 2008-07-25
Abstract: Waxy flour products exhibiting noncohesive textures and methods of making same are disclosed, with an example of the method comprising the steps of: Obtaining a waxy flour; and heat treating the waxy flour, wherein the pH of the waxy flour is not adjusted during this method.
Patent CA-2700232-A1 (CA)
Inventor: GILBERT STEVEN RAY
IPC: A61F13/20
Filed: 2008-09-23
Abstract: A method for making a tampon including providing a tampon pledget, and providing a compression/stabilization mold. The method includes moving the tampon pledget into the compression/stabilization mold via a transfer member, wherein the compression/stabilization mold is in an open position, and laterally compressing the tampon pledget in the compression/stabilization mold by closing the compression/stabilization mold to form a stabilized tampon. An apparatus for making a tampon and a tampon made by the method are also disclosed.
Patent CA-2701539-A1 (CA)
Inventor: BRAULT JEAN
IPC: G01N33/483
Filed: 2010-04-27
Abstract: A magnetic conductive recipient comprising: magnetic field via magnetized water. This process provides means for drug delivery in a molecular state, control of blood circulation, control of internal and / or external cell organism functions, including MWRI (magnetic water resonance imaging).
Patent CA-2703100-A1 (CA)
Inventor: HEIDER AXEL
IPC: H04L29/06
Filed: 2008-10-15
Abstract: On a portable data carrier (2) with a communication interface (5) and a control device (5) [sic] the control device (4) allows a transaction in a communication network (10) between a communication device (1) connected with the data carrier (2) via the communication interface (5) and a network server (3). For this purpose the control device (4) sends, in response to a request (S2; S 15) concerning a transaction between the communication device (1) and a network server (3), received from the connected communication device (1) via the communication interface (5), a request redirection message (S3; S19) concerning the transaction to the communication device (1).
Patent CA-2703629-A1 (CA)
Inventor: ADAMS PATTON M
IPC: B01J7/00
Filed: 2008-12-02
Abstract: Pressure swing adsorption (PSA) assemblies and hydrogen-producing fuel processing assemblies and/or fuel cell systems including the same. The PSA assemblies include, or are utilized with, combustion fuel stream supply systems that are adapted to regulate the flow of a byproduct stream from the PSA assembly for delivery to a heating assembly for use as a combustible fuel stream, such as to maintain at least a hydrogen-producing region of the fuel processing system at a hydrogen-producing temperature or range of temperatures. In some embodiments, the combustion fuel stream supply system is configured to ensure that the supply of combustible fuel from the PSA assembly to the heating assembly contains at least a sufficient fuel value, such as to maintain at least the hydrogen-producing region at or within a predetermined hydrogen-producing temperature or range of temperatures.
Patent CA-2705421-A1 (CA)
Title: Method for the producion of cyclic diesters of l-, d- and d,l-lactic acids
Inventor: RAFLER GERALD
IPC: C08G63/08
Filed: 2008-11-14
Abstract: A method for producing L,L-, D,D-, D,L- or meso-dilactide, comprising polycondensation and/or polytransesteriication of L-, D- or D,L-lactic acid or esters thereof to form high-molecular-weight polyesters of L-, D- or D,L-lactic acid (polylactic acids), and cyclodepolymerisation of the polylactic acids to form dilactides, wherein the high-molecular-weight polyesters of the L-, D- or D,L-lactic acid can be produced in the presence of hydrolysis-stable metal compounds acting as a catalyst.
Patent CA-2705793-A1 (CA)
Inventor: SMITH EMERY
IPC: A61M5/19
Filed: 2008-11-14
Abstract: A dual lumen syringe (10) includes a body (12) having a pair of elongate cavities or lumens (14, 16) formed therein. A directional valve (24, 32) is associated with each lumen. The valve is alternated between the first position wherein the lumen is communicably connected to a fluid inlet (28, 36) and a second position wherein the lumen is connected with a fluid outlet (26, 34). There are a pair of elongate plungers (102, 108), which are fixedly interconnected by a handle (114). Each plunger is received and longitudinally slidable in a reciprocating manner through a respective lumen. The valves are switched to a first position wherein the lumens are interconnected with the fluid inlets and the plunger is retracted to aspirate fluids through the respective inlets and into the lumens. The valves are then switched to a second position to communicably interconnect the lumens with the outlets. The plungers are then simultaneously driven inwardly through the respective lumens to drive the fluids simultaneously through the outlets to a dispensing tip (50) permanently connected to the body and in communication with the outlets.
Patent CA-2706043-A1 (CA)
Inventor: PUGIN BENOIT
IPC: C07C231/12
Filed: 2008-11-14
Abstract: Compounds of the formula I, in the form of mixtures comprising predominantly one enantiomer or in the form of pure enantiomers, secondary phosphine-Q-P*(=O)HR1 (I) in which secondary phosphine is a C-bonded, secondary phosphine group -P(R)2; in which R is in each case independently hydrocarbon radicals or heterohydrocarbon radicals; Q is a bivalent, achiral, aromatic base skeleton, a bivalent, achiral ferrocene base skeleton, an optionally substituted bivalent cycloalkane or heterocycloalkane skeleton, or a C1-C4-alkylene skeleton, and in which base skeletons a secondary phosphine group is bonded directly to a carbon atom, or, in the case of cyclic base skeletons, directly to a carbon atom or via a C1-C4-alkylene group, and in which base skeletons a P-chiral group -P*(O)HR1 is bonded to a carbon atom such that the phosphorus atoms are linked via 1 to 7 atoms of a carbon chain optionally interrupted by heteroatoms from the group of O, S, N, Fe or Si; P*  is a chiral phosphorus atom; and R1 is a hydrocarbon radical, a C-bonded heterohydrocarbon radical or a ferrocenyl radical, with the proviso that R1 is an achiral ferrocenyl radical when Q is an achiral ferrocenyl base skeleton. Metal complexes of these ligands in a molarratio of ligand to metal of about 1.3:1 to 0.9:1 are homogeneous catalysts for asymmetric addition reactions, particularly hydrogenations.
Patent CA-2706735-A1 (CA)
Inventor: TANG PENG CHO
IPC: A61P3/10
Filed: 2008-11-27
Abstract: Tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), their preparation methods, pharmaceutical compositions containing the derivatives and uses thereof as medicaments, especially as dipeptidyl peptidase IV inhibitor, wherein the substituents of formula (I) are defined as same as the description.     (see formula I)
Patent CA-2706901-A1 (CA)
Inventor: BATTERSBY NIGEL STEWART
IPC: C10M105/04
Filed: 2008-12-04
Abstract: The present invention relates to a base oil composition comprising at least one or more hydrogenated polymethylated triterpenes of the general formula C n H(2n+2) .
Patent CA-2707918-A1 (CA)
Inventor: MIYASHITA HARUMITSU
IPC: G11B20/18
Filed: 2010-02-01
Abstract: A reproduction signal evaluation unit has: a pattern detection section (101) for extracting, from a binary signal, a specific state transition pattern which has a possibility of causing a bit error; a differential metric computing section (102) for computing a differential metric based on the binary signal of the extracted state transition pattern; an error computing section (116) for computing an error rate predicted based on an integration value that is integrated by an integration section (125), a count value that is counted by a pattern count section (124), an integration value that is integrated by another integration section (105), and a count value that is counted by another pattern count section (104), and a standard deviation computing section (120) for computing a standard deviation based on the computed error rate.
Patent CA-2710345-A1 (CA)
Inventor: QUATTROPANI ANNA
IPC: A61K31/4245
Filed: 2008-12-17
Abstract: The invention relates to compounds of formula (I), wherein R1, R2, R a, R b, X  have the meanings given in claim 1.  The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
Patent CA-2710658-A1 (CA)
Title: Power injector with decay constant functionality
Inventor: FAGO FRANK M
IPC: A61M5/00
Filed: 2009-08-18
Abstract: A power injector having power injector control logic with a decay constant cross-reference and one or more injection protocols that provide an exponentially decaying flow rate injection is disclosed. The decay constant cross-reference stores flow rate decay constant information to provide the above-noted exponentially decaying flow rate injection on a model or model number basis for an imaging unit to be used in conjunction with the power injector for an imaging operation. The decay constant cross-reference may be searched by entering a model, model number, or some other identifier for the corresponding imaging unit, or the decay constant cross-reference may in the form of a drop-down menu or the like that lists a plurality of model or model numbers of imaging units along with their associated flow rate decay constant value.
Patent CA-2710745-A1 (CA)
Inventor: LOUIS FABIENNE
IPC: A61Q19/00
Filed: 2009-01-12
Abstract: L'invention se rapporte à une composition comprenant, dans un milieu physiologiquement acceptable, au moins un rétinoïde, du peroxyde de benzoyle dispersé et un gélifiant de la famille des carraghénanes.
Patent CA-2711773-A1 (CA)
Inventor: MEDVEDEV OLEG OLEGOVICH
IPC: E21B43/26
Filed: 2008-01-31
Abstract: This invention relates hydraulic fracturing in subterranean formations and, more particularly, to methods for opti-mizing fracture conductivity.
Patent CA-2712333-A1 (CA)
Inventor: PATTERSON BARBARA
IPC: G06Q40/00
Filed: 2009-01-23
Abstract: System for conducting a financial transaction with a single financial presentation device linked to multiple financial accounts stores financial account information of multiple financial accounts associated with the presentation device, and a set of predetermined rules for determining which of the financial accounts is to be used to conduct a financial transaction. A linked-account processing program receives an authorization request for the financial transaction which has been initiated at a merchant's computer using the presentation device. The program determines whether the presentation device is associated with multiple financial accounts, and if so, selects one account among the multiple linked financial accounts based on the predetermined set of rules, and routes the authorization request to an issuer of the selected financial account.
Patent CA-2715330-A1 (CA)
Inventor: SEBER BRETT P
IPC: B26B1/04
Filed: 2009-02-11
Abstract: Aspects of the disclosure include a tool (1). The tool may include a working portion, e.g. a blade (12), and a holding portion, e.g., a blade holder, wherein the blade and the blade holder (10) are coupled in such a manner that the blade may be positioned in a plurality of configurations with respect to the blade holder. The blade and blade holder may include one or more of an engagement element (28, 30) and/or engagement element receiver (48) that are configured for being coupled together in such a manner that the blade is substantially prevented from moving relative to the blade holder. The blade and/or blade holder may include a plurality of engagement elements and corresponding engagement, element receivers such that the blade is capable of being moved incrementally with respect to the blade holder. Also provided are methods of using the tool as well as specialized packaging for offering the tool for sale.
Patent CA-2717545-A1 (CA)
Inventor: KEEN BRIAN T
IPC: A01P1/00
Filed: 2009-03-12
Abstract: Hybrid strategies generally involve treating biodegradable substrates with preservative compositions having at least two phases in which the metal biocide is distributed among at least the two phases and via equilibrium reactions moves between the two phases. Both phases are caused to contact the substrate in a manner so that the phases are in contact with each other during at least a portion of the treatment. In illustrative embodiments, the first phase is a liquid phase comprising complexed metal biocide dissolved in a liquid carrier, while the second phase comprises particles comprising the metal biocide, often precipitated and/or colloidal particles. The strategies and related compositions, processes, and treatments are hybrid in the sense that the strategies include both heterogeneous (insoluble) and homogeneous metal biocide constituents. Unlike heterogeneous strategies, hybrid strategies are less sensitive to particle size constraints and may use biocide particles with a wider range of particle sizes. Unlike homogeneous strategies, hybrid strategies are less sensitive to pH and may use a wider range of complexing agents, including mildly alkaline amines such as triethanolamine.
Patent CA-2722374-A1 (CA)
Inventor: HOLM RENE
IPC: A61K31/4965
Filed: 2009-05-07
Abstract: The invention relates to methods of treating cognitive dysfunction and improving cognitive functioning comprising the administration of tran5-4-((1R,3S)-6-chloro-3-phenylindan-l-yl)- 1,2,2-trimethylpiperazine or a pharmaceutically acceptable salt thereof to a patient in need thereof. Moreover the invention relates to an improved binder in a composition comprising 4-((1R, 3S)-6-chloro-3-phenylindan- 1 -yl)- 1,2,2-trimethylpiperazine.
Patent CA-2731494-A1 (CA)
Inventor: MARTIN BENJAMIN
IPC: A61K39/385
Filed: 2009-08-06
Abstract: A process for preparing a nicotine-based hapten of formula (I) or a salt or solvate thereof, wherein n, R1 and R2 have the meanings as indicated in the specification. The nicotine-based hapten forms part of a smoking cessation vaccine.
Patent CA-2735869-A1 (CA)
Title: Procede optique pour la detection de la maladie d'alzheimer
Inventor: KORONYO MAYA
IPC: C12Q1/00
Filed: 2009-09-18
Abstract: La présente invention concerne un procédé d'imagerie optique non invasif pour surveiller des événements pathologiques précoces spécifiques de la maladie d'Alzheimer (AD), tels que le développement, la quantité et l'emplacement de plaques amyloïdes. La capacité à surveiller de tels événements fournit une base pour établir, entre autres, un diagnostic de la maladie d'Alzheimer, un pronostic et une évaluation de thérapies potentielles. De plus, la présente invention présente de nouveaux procédés pour traiter la maladie d'Alzheimer et des affections rétiniennes associées à la maladie d'Alzheimer. La détection de plaque Aß dans des cerveaux vivants est extrêmement limitée, en particulier à une résolution élevée; par conséquent, la présente invention est fondée sur des études qui se concentrent sur les yeux, en tant qu'alternatives à des tissus dérivés du cerveau, qui peuvent être imagés directement, de manière répétitive et non invasive.
Patent CA-2735876-A1 (CA)
Inventor: MEDYNSKI PAUL FRANKLIN
IPC: H04W84/16
Filed: 2011-03-30
Abstract: An improved method of configuring a communication system to extend the features of enterprise telephony to the mobile devices is disclosed. A Private Branch eXchange (PBX) system is configured to respond to a configuration telephone number by routing call control for the configuration number to a Service Management Platform (SMP). A  system can be configured to determine an enterprise extension associated with an enterprise account in the domain of the SMP. The system can direct a mobile communication device associated with the enterprise account to call the configuration telephone number, and to communicate the determined enterprise extension and an authentication token of the enterprise account.
Patent CA-2736251-A1 (CA)
Inventor: GERBERDING BRENT
IPC: A61B17/08
Filed: 2009-09-04
Abstract: Implantable devices for placement at a cavity or opening such as an aneurysm are disclosed. The implantable devices, in a deployed condi-tion, have a generally inverted U-shaped profile with a curved or angled frame-work support structure sized and configured for placement in proximity to tis-sue surrounding the opening and anchoring legs extending proximally from the framework structure sized and configured to contact the wall of a neighboring lumen at opposed locations. Occlusive and semi-occlusive membranes may be associated with the framework support structure and deployed over the open-ing to provide exclusion of the opening and flow diversion. Proximal anchor-ing segments providing additional lumen wall surface area contact for the im-plantable device following deployment may be incorporated.
Patent CA-2737831-A1 (CA)
Inventor: PALLE P VENKATA
IPC: A61P3/10
Filed: 2009-09-17
Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts, to formulations and uses in the treatment of metabolic disorders.
Patent CA-2738367-A1 (CA)
Title: Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
Inventor: GRAEFE-MODY EVA ULRIKE
IPC: A61K31/522
Filed: 2009-10-15
Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.
Patent CA-2738418-A1 (CA)
Inventor: MARTIN STEVEN C
IPC: C12N1/00
Filed: 2011-04-29
Abstract: There is provided a process of modulating inputs to a photobioreactor based on a change in the rate of supply of carbon dioxide, to the photobioreactor, from a gaseous exhaust material producing process.
Patent CA-2743038-A1 (CA)
Inventor: LEPINE RICHARD
IPC: B27N3/02
Filed: 2009-10-20
Abstract: There is provided an embossed particleboard, which can be used, for example, as a siding. The particleboard comprises a monolayer embossed particleboard including wood particles having an average size of less than 4 mm, a resin, and optionally a sizing agent. There is also provided a method of manufacturing a wood-based product such as a siding. The method comprises embossing and pressing in a single step a monolayer mat comprising wood particles having an average size of less than 4 mm and a resin, so as to obtain an embossed monolayer particleboard siding.
Patent CA-2743904-A1 (CA)
Inventor: MYC ANDRZEJ
IPC: A61P35/00
Filed: 2009-11-17
Abstract: The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
Patent CA-2744402-A1 (CA)
Title: Procede de purification de methacrylate de methyle
Inventor: JOHNSON DAVID WILLIAM
IPC: C07C67/60
Filed: 2009-12-11
Abstract: L'invention concerne un procédé de purification de méthacrylate de méthyle (MMA). Le procédé implique la mise en contact du MMA liquide contenant des impuretés avec une résine d'acide sulfonique, en présence de formaldéhyde ou d'une source de méthylène ou d'éthylène appropriée de formule I. R5 et R6 sont indépendamment choisis parmi des hydrocarbures en C1-C12 ou H ; X représente O ou S ; n est un nombre entier de 1 à 100 ; et m vaut 1 ou 2. Le composé de formule I peut être une source appropriée de formaldéhyde.
Patent CA-2744543-A1 (CA)
Title: Verin a course declenchee pour dispositif de securite integre a un vehicule automobile, pour la protection d'un pieton en cas de choc frontal
Inventor: BORG EVRARD
IPC: F15B15/19
Filed: 2009-11-24
Abstract: Vérin à course déclenchée à retour arrière amorti. Selon l'invention, le vérin abrite un piston (15) un générateur de gaz (19) incluant une charge pyrotechnique à combustion rapide et abrite en outre une charge pyrotechnique (38) à combustion plus lente que celle dudit générateur de gaz (19).